Table E2.
Outcomes at Different Time Points after the Index Procedure
| Outcome | Preweighting |
Postweighting |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | Cumulative incidence |
P value | Hazard ratio (95% CI) | Cumulative incidence |
P value | ||||
| Primary outcome | Time point | Intravascular US | Non–intravascular US | Intravascular US | Non–intravascular US | ||||
| Composite of all-cause mortality, all-cause hospitalization, or target vessel repeat intervention (intravascular US vs non–intravascular US) | 1 mo | 0.29 (0.26–0.32) | 3.94% | 12.99% | <.001 | 0.43 (0.39–0.49) | 4.58% | 10.19% | <.001 |
| 3 mo | 0.47 (0.44–0.50) | 12.96% | 25.07% | <.001 | 0.61 (0.57–0.66) | 13.67% | 20.91% | <.001 | |
| 6 mo | 0.52 (0.49–0.55) | 20.65% | 34.93% | <.001 | 0.67 (0.63–0.71) | 21.67% | 29.98% | <.001 | |
| 12 mo | 0.58 (0.55–0.61) | 33.95% | 49.03% | <.001 | 0.72 (0.69–0.76) | 34.91% | 43.40% | <.001 | |
| All-cause mortality | 1 mo | 0.09 (0.07–0.12) | 0.57% | 5.95% | <.001 | 0.16 (0.13–0.20) | 0.70% | 4.28% | <.001 |
| 3 mo | 0.14 (0.12–0.16) | 1.80% | 11.90% | <.001 | 0.24 (0.21–0.28) | 2.17% | 8.60% | <.001 | |
| 6 mo | 0.18 (0.16–0.20) | 3.54% | 17.82% | <.001 | 0.30 (0.27–0.34) | 4.24% | 13.04% | <.001 | |
| 12 mo | 0.21 (0.19–0.23) | 6.18% | 24.95% | <.001 | 0.33 (0.30–0.36) | 7.07% | 19.31% | <.001 | |
| All-cause hospitalization | 1 mo | 0.40 (0.36–0.45) | 3.67% | 8.91% | <.001 | 0.58 (0.51–0.66) | 4.22% | 7.15% | <.001 |
| 3 mo | 0.45 (0.41–0.49) | 8.36% | 17.58% | <.001 | 0.62 (0.57–0.68) | 9.35% | 14.54% | <.001 | |
| 6 mo | 0.51 (0.48–0.55) | 14.55% | 25.92% | <.001 | 0.68 (0.63–0.73) | 15.81% | 21.98% | <.001 | |
| 12 mo | 0.59 (0.56–0.63) | 26.67% | 38.85% | <.001 | 0.75 (0.71–0.80) | 27.85% | 34.07% | <.001 | |
| Target vessel repeat intervention* | 1 mo | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 3 mo | 1.54 (1.29–1.83) | 4.60% | 3.04% | <.001 | 1.38 (1.16–1.64) | 4.30% | 3.15% | <.001 | |
| 6 mo | 1.37 (1.19–1.58) | 6.60% | 4.92% | <.001 | 1.28 (1.11–1.47) | 6.40% | 5.11% | <.001 | |
| 12 mo | 1.26 (1.12–1.43) | 9.00% | 7.41% | <.001 | 1.23 (1.09–1.39) | 8.70% | 7.25% | <.001 | |
| Secondary outcome | |||||||||
| Composite of stent thrombosis, embolization, or restenosis (intravascular US vs non–intravascular US) | 1 mo | 0.23 (0.16–0.33) | 0.34% | 1.46% | <.001 | 0.35 (0.24–0.49) | 0.40% | 1.14% | <.001 |
| 3 mo | 0.23 (0.18–0.30) | 0.67% | 2.82% | <.001 | 0.35 (0.27–0.45) | 0.79% | 2.26% | <.001 | |
| 6 mo | 0.23 (0.18–0.28) | 0.91% | 3.92% | <.001 | 0.36 (0.29–0.45) | 1.14% | 3.06% | <.001 | |
| 12 mo | 0.22 (0.18–0.27) | 1.30% | 5.76% | <.001 | 0.32 (0.27–0.39) | 1.55% | 4.86% | <.001 | |
| Stent thrombosis | 1 mo | 0.19 (0.12–0.30) | 0.20% | 1.04% | <.001 | 0.29 (0.19–0.46) | 0.23% | 0.78% | <.001 |
| 3 mo | 0.20 (0.15–0.27) | 0.42% | 2.05% | <.001 | 0.29 (0.21–0.39) | 0.48% | 1.68% | <.001 | |
| 6 mo | 0.20 (0.15–0.26) | 0.55% | 2.75% | <.001 | 0.31 (0.23–0.40) | 0.68% | 2.19% | <.001 | |
| 12 mo | 0.19 (0.15–0.24) | 0.77% | 4.01% | <.001 | 0.28 (0.22–0.36) | 0.90% | 3.22% | <.001 | |
| Stent embolization | 1 mo | 0.19 (0.04–1.04) | 0.01% | 0.07% | .056 | 0.17 (0.03–0.95) | 0.01% | 0.07% | .044 |
| 3 mo | 0.31 (0.08–1.15) | 0.03% | 0.09% | .079 | 0.44 (0.13–1.48) | 0.04% | 0.09% | .187 | |
| 6 mo | 0.11 (0.04–0.34) | 0.03% | 0.26% | <.001 | 0.18 (0.07–0.48) | 0.04% | 0.23% | <.001 | |
| 12 mo | 0.09 (0.03–0.28) | 0.03% | 0.33% | <.001 | 0.15 (0.06–0.40) | 0.04% | 0.28% | <.001 | |
| Stent restenosis | 1 mo | 0.28 (0.17–0.49) | 0.15% | 0.54% | <.001 | 0.45 (0.26–0.76) | 0.20% | 0.45% | 0.003 |
| 3 mo | 0.26 (0.17–0.38) | 0.28% | 1.08% | <.001 | 0.41 (0.28–0.60) | 0.36% | 0.89% | <.001 | |
| 6 mo | 0.26 (0.19–0.36) | 0.41% | 1.55% | <.001 | 0.40 (0.29–0.56) | 0.52% | 1.28% | <.001 | |
| 12 mo | 0.25 (0.19–0.33) | 0.62% | 2.44% | <.001 | 0.33 (0.25–0.43) | 0.75% | 2.32% | <.001 | |
CI = confidence interval; N/A = not available; US = ultrasound.
*
Target vessel repeat intervention cannot differentiate between ipsilateral and contralateral interventions. This includes a 30-day blanking period to account for staged procedures.